Clinical Safety and Preliminary Efficacy of Plasmid pUDK-HGF Expressing Human Hepatocyte Growth Factor (HGF) in Patients with Critical Limb Ischemia.

@article{Cui2015ClinicalSA,
  title={Clinical Safety and Preliminary Efficacy of Plasmid pUDK-HGF Expressing Human Hepatocyte Growth Factor (HGF) in Patients with Critical Limb Ischemia.},
  author={Shijun Cui and Lianrui Guo and Xiaoyan Li and Yongquan Gu and Jing-ya Fu and Lei Dong and Haifeng Song and Xuejing Chen and Yi Lu and Chunsheng Hu and Fengjun Xiao and Dan Zhu and Z X Wu and Qinglin Zhang},
  journal={European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery},
  year={2015},
  volume={50 4},
  pages={494-501}
}
OBJECTIVE Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease and a major unmet public health care need. This phase I clinical study was performed to assess the safety and preliminary efficacy of naked plasmid DNA (pUDK-HGF) expressing human hepatocyte growth factor (HGF) in patients with critical limb ischemia (CLI… CONTINUE READING